BioPharmSignal logoBioPharmSignal

Biotech News

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

Merus (MRUS)MerusEarnings

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 6 3% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company’s current operating plan, existing cash, cash equivalents, including

Related news

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

APGEApogee Therapeutics2026-08-10 11:00 EST

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

ALECAlector2026-08-06 20:05 EST

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Merus

Merus is a clinical-stage antibody company focused on precision oncology and bispecific antibody development. Its platform is built around engineered immunology and cancer programs.

Recent company news

MRUSMerus2025-12-12 07:54 EST

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

MRUSMerus2025-11-17 12:15 EST

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUSMerus2025-10-24 14:00 EST

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

MRUSMerus2025-10-14 11:30 EST

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MRUSMerus2025-10-13 16:00 EST

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States